Zonisamide

Research output: Contribution to journalReview article

93 Scopus citations

Abstract

Zonisamide (ZNS) is a broad-spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization-related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes. Its pharmokinetic profile is favorable, with a long half-life and low protein binding. However, its insolubility may make the development of a parenteral formulation difficult. Its safety profile is good, although teratogenicity in animal models is of concern. Adult doses of 400-600 mg per day in two doses, with blood levels from 20 to 30 mg/ml, appear to be effective.

Original languageEnglish (US)
Pages (from-to)s23-s29
JournalEpilepsia
Volume40
Issue numberSUPPL. 5
StatePublished - Jan 1 1999

Keywords

  • Efficacy
  • Epilepsy
  • New antiepileptic drug
  • Side effects
  • Zonisamide

Fingerprint Dive into the research topics of 'Zonisamide'. Together they form a unique fingerprint.

  • Cite this

    Leppik, I. E. (1999). Zonisamide. Epilepsia, 40(SUPPL. 5), s23-s29.